Abstract | PURPOSE:
Astaxanthin (AST) is a carotenoid found in marine animals and vegetables. The purpose of the present study was to investigate the effect of AST on the development of experimental choroidal neovascularization (CNV) with underlying cellular and molecular mechanisms. METHODS: RESULTS: The index of CNV volume was significantly suppressed by treatment with AST compared with that in vehicle-treated animals. AST treatment led to significant inhibition of macrophage infiltration into CNV and of the in vivo and in vitro expression of inflammation-related molecules, including VEGF, IL-6, ICAM-1, MCP-1, VEGFR-1, and VEGFR-2. Importantly, AST suppressed the activation of the NF-kappaB pathway, including IkappaB-alpha degradation and p65 nuclear translocation. CONCLUSIONS: AST treatment, together with inflammatory processes including NF-kappaB activation, subsequent upregulation of inflammatory molecules, and macrophage infiltration, led to significant suppression of CNV development. The present study suggests the possibility of AST supplementation as a therapeutic strategy to suppress CNV associated with AMD.
|
Authors | Kanako Izumi-Nagai, Norihiro Nagai, Kazuhiro Ohgami, Shingo Satofuka, Yoko Ozawa, Kazuo Tsubota, Shigeaki Ohno, Yuichi Oike, Susumu Ishida |
Journal | Investigative ophthalmology & visual science
(Invest Ophthalmol Vis Sci)
Vol. 49
Issue 4
Pg. 1679-85
(Apr 2008)
ISSN: 0146-0404 [Print] United States |
PMID | 18385091
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Angiogenesis Inhibitors
- Anti-Inflammatory Agents, Non-Steroidal
- Ccl2 protein, mouse
- Chemokine CCL2
- I-kappa B Proteins
- Icam1 protein, mouse
- Interleukin-6
- NF-kappa B
- Nfkbia protein, mouse
- Vascular Endothelial Growth Factor A
- Xanthophylls
- vascular endothelial growth factor A, mouse
- Intercellular Adhesion Molecule-1
- NF-KappaB Inhibitor alpha
- astaxanthine
- Vascular Endothelial Growth Factor Receptor-1
- Vascular Endothelial Growth Factor Receptor-2
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Animals
- Anti-Inflammatory Agents, Non-Steroidal
(therapeutic use)
- Blotting, Western
- Chemokine CCL2
(metabolism)
- Choroid
(metabolism)
- Choroidal Neovascularization
(metabolism, prevention & control)
- Disease Models, Animal
- Enzyme-Linked Immunosorbent Assay
- I-kappa B Proteins
(metabolism)
- Injections, Intraperitoneal
- Intercellular Adhesion Molecule-1
(metabolism)
- Interleukin-6
(metabolism)
- Male
- Mice
- Mice, Inbred C57BL
- NF-KappaB Inhibitor alpha
- NF-kappa B
(metabolism)
- Pigment Epithelium of Eye
(metabolism)
- Vascular Endothelial Growth Factor A
(metabolism)
- Vascular Endothelial Growth Factor Receptor-1
(metabolism)
- Vascular Endothelial Growth Factor Receptor-2
(metabolism)
- Xanthophylls
(therapeutic use)
|